Due to antigen specificity, blocking monoclonal antibodies have proven to be effective when combined with chemotherapy, such as rituximab for B-Cell lymphoma, trastuzumab for HER2-positive cancer, cetuximab for colorectal carcinoma, and alemtuzumab for chronic lymphocytic leukemia. Here, ERBB2 is linked to B-cell non-Hodgkin lymphoma.